MicroRNA expression profiles associated with development of drug resistance in Ehrlich ascites tumor cells

Susanne Husted1, Rolf Søkilde, Lene Rask

  • 1Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.

Molecular Pharmaceutics
|September 9, 2011
PubMed

Insights

Multidrug resistance (MDR) in cancer involves microRNAs (miRNAs). This study identified specific miRNA expression patterns associated with drug resistance in cancer cells, offering insights into MDR development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Multidrug resistance (MDR) is a significant challenge in cancer chemotherapy.
  • MicroRNAs (miRNAs) are key regulators of gene expression and may play a role in MDR.

Purpose of the Study:

  • To identify miRNA expression changes associated with drug resistance in cancer cells.
  • To investigate the role of miRNAs in the development of multidrug resistance.

Main Methods:

  • Utilized an LNA-enhanced microarray platform to analyze miRNA expression profiles.
  • Compared miRNA expression in sensitive and progressively resistant Ehrlich ascites tumor (EAT) cell lines.

Main Results:

  • Identified distinct miRNA expression patterns related to growth, hypoxia, and drug resistance.
  • Found specific miRNA clusters (e.g., miR-183∼miR-96∼miR-182, miR-200b∼miR-200a∼miR-429) upregulated and others (e.g., miR-125b-5p, miR-30d∼miR-30b) downregulated in resistant cells.
  • Observed potential contributions of miRNA targets like Zeb1/Zeb2 to drug resistance, but no direct correlation with resistance levels.

Conclusions:

  • Observed miRNA expression patterns may reflect underlying genomic instability in tumor cells.
  • Further research is needed to elucidate the complex role of miRNA networks in MDR development.